The European League Against Rheumatism (EULAR) 2012 Noteworthy Takeaways
Among all oral options for the treatment of Rheumatoid Arthritis (RA), JAK inhibitors are ready to reach the market but the debate will continue – whether targeting specific JAK-1, 2, &3 or a multipronged approach like JAK 1/2, 1/3 is better? JAK1 may be the most suitable target as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and specific association with the common gamma chain of the IL-2 receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. In addition, systematic review of the safety of protein kinase inhibitors in clinical trials in RA suggested that JAK inhibitors (despite change in lipid profile) may be … For more detail, please read our report, released on 12th June on EULAR 2012, titled “EULAR 2012: Noteworthy Takeaways”.
COMPANIES MENTIONED
All
All
